Tot Biopharmaceutical

China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop antibody drug conjugates (ADCs) leveraging Escugen’s linker-payload technology, EZWi Fit, and Foreseen’s first-in-class antibodies and targets. This collaboration aims to create ADCs with enhanced drug efficacy and resistance in various tumor models, offering differentiated clinical…